MedTrace Logo

Thyroxine Replacement in Organ Donors

NCT00238030 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2011-01-05

No results posted yet for this study

Summary

To compare oral versus intravenous administration of thyroid hormone: 1) for reversibility of hemodynamic instability in organ donors, and, 2) the pharmacokinetics of oral vs iv thyroid administration

Conditions

  • Brain Death

Interventions

DRUG

L-thryoxine

2 mcg/kg iv or 2 mcg/kg po at time of enrollment

DRUG

iv thryoxine

thyroxine 2 mcg/kg iv

Sponsors & Collaborators

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Michael D Sharpe, MD FRCPC · London Health Sciences Centre-UC+

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2009-05-31
Completion
2010-10-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00238030 on ClinicalTrials.gov